Home › Multiple Myeloma › Florida › Pembroke Pines
Multiple Myeloma clinical trials in Pembroke Pines, FL
3 studies for Multiple Myeloma are looking for participants at sites in and around Pembroke Pines (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
RecruitingPhase 3
- Memorial Cancer Institute, Pembroke Pines
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RecruitingPhase 1/2
- GSK Investigational Site, Pembroke Pines
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
RecruitingPhase 3
- GSK Investigational Site, Pembroke Pines
About Multiple Myeloma
Multiple myeloma is a cancer that begins in plasma cells, a type of white blood cell. Discover symptoms, diagnostic tests, and treatments for myeloma.
More about Multiple Myeloma on MedlinePlus
Multiple Myeloma trials in other cities
- New York City, NY59 studies
- Boston, MA45 studies
- Atlanta, GA42 studies
- Houston, TX39 studies
- Durham, NC36 studies
- Nashville, TN31 studies
- Denver, CO26 studies
- St. Louis, MO26 studies
- Rochester, MN25 studies
- Columbus, OH25 studies
- Chicago, IL24 studies
- Milwaukee, WI23 studies
Other studies in Pembroke Pines
- Obesity10 studies
- Overweight8 studies
- Non-Small Cell Lung Cancer7 studies
- Type 2 Diabetes7 studies
- Acute Myeloid Leukemia5 studies
- Lung Cancer5 studies
- Kidney Diseases3 studies
- High Blood Pressure3 studies
- IGA Glomerulonephritis3 studies
- Heart Failure3 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.